Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Immunovant, Inc. (IMVT : NSDQ)

• Company Description    Immunovant Inc. is a clinical-stage biopharmaceutical company focused on autoimmune diseases. The company's product candidate consists of IMVT-1401 which is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor which is in clinical stage. Immunovant Inc. is based in New York, United States. Number of Employees: 68

• Price / Volume Information    Yesterday's Closing Price: $4.02 Daily Weekly Monthly 20 Day Moving Average: 379,467 shares Shares Outstanding: 116.40 (millions) Market Capitalization: $467.91 (millions) Beta: 0.96 52 Week High: $16.05 52 Week Low: $3.71 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -19.44% -11.73% 12 Week -26.78% -20.55% Year To Date -52.82% -43.89%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 320 WEST 37TH STREET - NEW YORK,NY 10018 USA ph: 917-580-3099 fax: - info@immunovant.com http://www.immunovant.com

• General Corporate Information    Officers Peter Salzmann - Chief Executive Officer and Director Frank M. Torti - Chairman Pamela Yanchik Connealy - Chief Financial Officer Andrew Fromkin - Director Douglas Hughes - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 45258J102 SIC: 2836 Fiscal Year Fiscal Year End: March Last Reported Quarter: 12/01/21 Next Expected EPS Date: 06/07/22 Share - Related Items Shares Outstanding: 116.40 Most Recent Split Date: (:1) Beta: 0.96 Market Capitalization: $467.91 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.40 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.67 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 06/07/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.92 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -12.50% vs. Previous Quarter: -2.86% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - - 12/31/21 - -30.63 09/30/21 - -30.01 ROA 03/31/22 - - 12/31/21 - -28.83 09/30/21 - -28.46 Current Ratio 03/31/22 - - 12/31/21 - 14.87 09/30/21 - 19.86 Quick Ratio 03/31/22 - - 12/31/21 - 14.87 09/30/21 - 19.86 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - - 12/31/21 - 4.39 09/30/21 - 4.66 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - - 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - - 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©